glp-1/gip dual agonist lilly LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes GLP-1 use tripled among non-diabetics,

These findings highlight the potential clinical importance of achieving and maintaining weight loss after GLP-1-based treatment initiation. Meeting: European Congress on Obesity 2026 (ECO2026) Never miss a breakthrough: Join the SciTechDaily newsletter

Click Sales Inc

& Scholtz, J

In the SURPASS-2 head-to-head against semaglutide for diabetes, tirzepatide produced significantly greater A1c reductions

At Present, Single-agonist Segment Occupies the Largest Share of the GLP-1 Market In terms of the type of GLP-1 agonist, the market is segmented into single-agonist, dual-agonist and tri-agonist

Several alternatives can support meaningful weight loss when used with medical guidance